Alnylam Pharmaceuticals, Inc. reiterated earnings guidance for the full year 2024. For the period, the company expects combined net product revenues for ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO to be $1,400 million to $1,500 million and net revenues from collaborations and royalties to be $325 million to $425 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.8 USD | +2.33% | +2.93% | -20.18% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.18% | 19.33B | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B | |
-9.14% | 11.06B |
- Stock Market
- Equities
- ALNY Stock
- News Alnylam Pharmaceuticals, Inc.
- Alnylam Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2024